Figure 1: FACS analysis confirms that HuGEMM CTLA-4 knock in models express human CTLA-4 on T cells.
HuGEMM™ CTLA-4 Mouse Model Description
The HuGEMM CTLA-4 mouse model is a chimeric tumor model where the mouse immune system is functional and the CTLA-4 receptors have been humanized for a more translational immune response.
The CTLA-4 model was developed by replacing mouse exons 2 and 3 with their human counterparts (murine exons 1 and 4 remain). This allows the receptor to be recognized by therapeutic antibodies of interest, and enables the ability to test the therapeutic efficacy directly in the mouse model.
CTLA-4 plays an important role in the immune response, acting as an immune checkpoint, downregulating T cell function, and inhibiting excessive expansion of activated T cells.
Benefits of HuGEMM Models
- Humanized drug targets eliminate and reduce interspecific (species) effects of the compound providing a platform to evaluate therapeutic antibodies which are not cross-reactive to the mouse protein
- Enables the evaluation of specific human biological therapies in vivo when no mouse ortholog is available
- Provides an efficient method to study a range of targets for human immunotherapies
CTLA-4 Model Characterization Data
Figure 1: FACS analysis confirms that HuGEMM CTLA-4 knock in models express human CTLA-4 on T cells.
×
Figure 2: Validation of HuGEMM CTLA-4 with an ipilimumab analog. Tumor growth inhibition of the MC38 model is observed following treatment with the anti-hCTLA-4 antibody.
Figure 2: Validation of HuGEMM CTLA-4 with an ipilimumab analog. Tumor growth inhibition of the MC38 model is observed following treatment with the anti-hCTLA-4 antibody.
